- [2] Iguelouane N, Skandour D, Rochdi Y, Nouri H, Aderdour L, et A. Raji. Les manifestations ORL dans les maladies systémiques: à propos d'une série de 200 cas. 121e Congrès 2014, 11–13 octobre;131(4). Paris – Palais des Congrès.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5708

AB0350 TEMPORO-MANDIBULAR JOINT INVOLVEMENT IN RHEUMATOID ARTHRITIS

S. Zour¹, H. Mouana¹, A. Arfa¹, H. Hachfi², M. Jguirim¹, I. Bejjia¹, T. Mongi¹, M. Youness², N. bergaoui¹. ¹Rheumatology Department of Monastir University Hospital, Monastir; ²Rheumatology Department of Mahdia University Hospital, Mahdia, Tunisia

Background: Temporomandibular joint (TMJ) disorder in rheumatoid arthritis (RA) may be associated with significant osteoarticular destruction and may be responsible of significant functional impairment.

Objectives: We aimed in this study to determine the prevalence of TMJ involvement and its correlations with RA parameters.

Methods: We report a descriptive monocentric cross-sectional study of 90 consecutive RA, followed at the Rheumatology department of Monastir Teaching Hospital in Tunisia, during 06 months (November 2016 to April 2017) and 46 matched volunteers. Clinical assessment and stomatological examination were performed in all cases.

Results: Sixty-three RA patients out of 90 (70%) had TMJ involvement. TMJ painful mobilisation, mastication difficulties, swollen TMJ, dental malocclusion and limitation of mouth opening were noted in 55 (81%), 49 (74%), 20 (30.3%), 19 (29%) and 8 (12%) of cases, respectively. Compared with the control group, painful palpation of TMJ ($p < 0.000$) was significantly associated with RA.

In RA, TMJ disorder is more common in adults between 40 and 60 years of age, patients with HAQ>0.5 and a high total Vander Heijde Sharp radiographic score (SS). TMJ painful mobilisation is significantly associated with increased body mass index (BMI). Swollen TMJ is significantly associated with age (more frequent in elderly subjects), increased BMI, high RA disease activity (high DAS 28 ESR and/or DAS 28 CRP) and HAQ>0.5. Limitation of mouth opening is significantly associated with age (more common in elderly subjects), overweight, high methotrexate dose (20 mg/day), leflunomide and biotherapy use. Dental malocclusion was significantly associated with high doses corticosteroids (more than 5 mg/day). Mastication difficulties are significantly associated with more than 10 year RA duration, HAQ>0.5 and radiological impairment.

Conclusions: Temporomandibular disorder is frequent in RA (70%). TMJ disorder is observed especially in active (high DAS 28), serious (radiological impairment, HAQ>0.5) and advanced (more than 10 year duration) RA. Physicians must be careful to assess systematically TMJ in RA patients.

REFERENCE:

- [1] Aliko A, Ciancaglini R, Alushi A, Tafaj A, Ruci D. Temporomandibular joint involvement in rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. *International Journal of Oral and Maxillofacial Surgery* 2011;40:704–9.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5781

AB0351 DIFFERENTIAL PERCEPTION ABOUT THE CSDMARDS ON DRUG-INDUCED INTERSTITIAL LUNG DISEASE BETWEEN RHEUMATOLOGISTS AND NON-RHEUMATOLOGISTS

H. Kobayashi^{1,2}, T. Okubo¹, H. Oka¹, A. Aoki¹. ¹Rheumatology, Tokyo Medical University Hachioji Medical Center, Tokyo; ²Internal Medicine, Aihara Hospital, Sagami, Japan

Background: As disease modified anti-rheumatic-drugs (DMARDs) were the mainstay in the treatment of rheumatoid arthritis (RA), the opportunity for general physicians to also prescribe DMARDs has recently increased in Japan. After DMARDs were initiated by specialists, subsequent drug prescription by general physicians during remission should be expected¹. However, general physicians

are more likely than rheumatologists to feel it difficult to accept patients taking even conventional synthetics (cs) DMARDs but not biologics and such discomforts may be potential barriers to cooperative management between specialists and general physicians². One of the reasons is because some csDMARDs such as methotrexate and leflunomide may induce pneumonitis or worsen RA-related pre-existing interstitial lung disease (ILD) as a rare but severe adverse event³. To minimise the risk, rheumatologists may choose low-risk csDMARDs smartly when the patients are concomitant with risk factors on ILD.

Objectives: To measure the physicians' perspective toward the risk of each csDMARDs on drug-induced ILD and their attitude in prescribing the csDMARDs to a pre-existing ILD case.

Methods: A questionnaire was given in an internet survey to registered physicians who take care of more than ten patients with RA in Japan. Topics covered were i) how is the risk of each csDMARD for drug-induced lung injury compared to methotrexate, ii) which csDMARDs should be applied to a case with mild pneumonitis on the chest CT. Cross tabulation analysis and χ^2 test as a statistical analysis was performed.

Results: A total 184 physicians consisting of 66 rheumatologists (36%) and 118 non-rheumatologists (64%) responded. The physicians' mean age was 45 years old. The rheumatologists tended to belong to rheumatology and take care of more than 200 RA patients per month in university hospitals. On the other hand, the non-rheumatologists tended to belong to general medicine and manage less than 50 patients per month in their clinics. The csDMARDs except for methotrexate were more significantly prescribed by the rheumatologists. All rheumatologists but 24% of non-rheumatologists had managed RA patients with exacerbated ILD. On physicians' perspective toward the risk of each csDMARD, the rheumatologists considered that LEF was equal to or higher than MTX and that cyclosporine A (CyA), tacrolimus (TAC), salazosulfapyridine (SASP) was relatively safer (Figure A.). In cases with pre-existing ILD, more rheumatologists agreed to use the csDMARDs except for methotrexate and leflunomide. (Figure B.)

Abstract AB0351 – Figure 1. A) Physician's opinion about how is the risk of the following csDMARDs for drug-induced ILD compared to methotrexate. B) Physician's opinion about if the following csDMARDs should be applied to a case with mild ILD on the chest CT.

R: rheumatologists, non-R: non-rheumatologists, MTX: methotrexate, LEF: leflunomide, CyA: cyclosporine A, TAC: tacrolimus, SASP: salazosulfapyridine, BUC: bucillamine, IGU: iguratimod

Conclusions: We can find the gap of risk perception about each csDMARDs between rheumatologists and non-rheumatologist and the difference of attitude in prescribing to patients concomitant with risk factors. Considerable consensus and additional enlightenment to general physicians should be necessary.

REFERENCES:

- [1] Puchner R. Interface Management between General Practitioners and Rheumatologists-Results of a Survey Defining a Concept for Future Joint Recommendations. *PLoS One* 2016 Jan 7;11(1).
- [2] Garneau KL. Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement. *Arthritis Res Ther.* 2011;13(6).
- [3] Roubille C. Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review. *Semin Arthritis Rheum* 2014 Apr;43(5).

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3873

AB0352

SIGNIFICANCE OF OCCULT INFECTIONS IN INFLAMMATORY ARTHRITIS PATIENTS RECEIVING BIOLOGIC THERAPIES IN EAST LONDON

H. Alkomy, G. Qadir, O. Etomi, H. Tahir, A. Pakozdi. *Rheumatology, Barts Health, London, UK*

Background: Chronic hepatitis B virus (HBV) infection remains a significant global health problem. In high endemic areas like African and Asian countries, most infections occur from vertical transmission, whilst in western countries HBV is primarily acquired in adulthood. Either way, HBV can persist in infected hepatocytes lifelong, even if undetectable in the serum, allowing reactivation during immunosuppression. HBsAg carriers, those with detectable HBV viral load, or receiving concomitant corticosteroids are at greater risk. Most guidelines recommend screening for occult infections prior to starting biologic treatment including testing for HBV, HCV, HIV and TB infection.

Objectives: This study was carried out to estimate the prevalence of occult infections, particularly chronic HBV, in an East London rheumatology population receiving biologic therapies, and to evaluate the rate of HBV reactivation after starting treatment.

Methods: Inflammatory arthritis patients starting biologic therapies in Barts Health NHS Trust between August 2014 and August 2017 were identified from databases of Whipps Cross and Mile End Hospitals. Health records were reviewed focusing on HBV core antibody (HBcAb), HBV surface antigen (HBsAg), HBV DNA, HCV and HIV antibody status. Latent TB tests included IGRA and ELI-Spot assays.

Results: 757 patients were included in the study. Of those, 51 (6.7%) were HBcAb positive, 6 patients (0.8%) were HBsAg positive and two patients had low level HBV viraemia with detectable DNA antibody at baseline. 61% (n=31) of HBcAb positive patients were female, whilst 39% (n=20) were male, with median age of 58 years (IQR, 43–65). The ethnic distribution was the following: 43% asian (n=22; Bangladeshi or Pakistani), 29% african or afro-Caribbean black (n=15), and 18% white caucasian (n=9). The underlying rheumatological conditions included rheumatoid arthritis (59%), ankylosing spondylitis (33%) and psoriatic arthritis (8%). Fifteen patients (29%) received concomitant prophylactic anti-viral therapies (lamivudine, entecavir or tenofovir). After commencing biologic therapies, no HBV reactivation was noted in the HBcAb positive cohort. Intermittent mild transaminitis were detected on monitoring blood tests in 22% (n=11). The rate of latent TB infection was 11.5%; HCV IgG was detected in three patients, whilst HIV infection was absent in our cohort.

Conclusions: Approximately 50% of the patient population of Barts Health NHS Trust is coming from minority ethnic groups. Likely because of the diversity of the population, the prevalence of chronic HBV infection (HBsAg and HBcAb positives) in our East London rheumatology population receiving biologic therapies was higher than the national average (0.8% vs. 0.3%, respectively). No HBV reactivation was observed in the follow up period indicating that the risk of reactivation is relatively low. Nevertheless, for patients with evidence of previous infection (HBcAb positive) careful surveillance continues to be recommended.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6451

AB0353

GENETICALLY PREDISPOSITION AND PRO-INFLAMMATORY DYSREGULATIONS – CONNECTING RHEUMATOID ARTHRITIS AND MENTAL DISORDERS

I.C. Filipescu¹, L. Ghib¹, P. Juan Sainz², C. Perez-Sanchez³, C. Lopez-Pedraza⁴, A. Escudero⁵, L. Damian¹, L. Muntean¹, E. Collantes-Estévez⁵, S. Rednic¹.
¹Rheumatology Clinic, University of Medicine and Pharmacy, Cluj-Napoca, Romania; ²GENYO Centre for Genomics and Oncological Research, University of Granada, Granada; ³Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba; ⁴Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC); ⁵Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain

Background: Depressive and anxiety disorders are reported as the more prevalent psychiatric comorbidities in chronic inflammatory diseases and their occurrence has been correlated with higher serum levels of cytokines and chemokines (IL-6, IL-1, IL-12, IL-18, TNF- α , and even TNF-RI and TNF-RII). Some single nucleotide polymorphisms (SNPs) in TNF- α gene have been found to play a common part in pro-inflammatory alterations in patient with rheumatoid arthritis (RA) and depressive symptoms.

Objectives: To investigate the possible influence of four single-nucleotide polymorphism in the tumour necrosis factor receptor II (TNFR2) genes and development of psychiatric disorders in patients with active RA. The second aim was to evaluate some correlation between these SNPs, the level of four chemokines and the incidence of mental disorders.

Methods: We included 89 Caucasian patients with active RA treated in a tertiary Department of Rheumatology from Cluj-Napoca. All demographic, clinical, and biological data and RA comorbidities were completed. The presence of

depressions or anxiety was confirmed at the baseline by psychiatrist. Four potentially functional SNPs within TNFRSF1B (rs1061622, rs1062624, rs1061631, rs3397) were selected to be genotyped in all patients using PCR (KASPar) asASys (KBiosciences, Hoddesdon, Hertfordshire, UK) at the Centre for Genomics and Oncological Research (GENYO), Granada, Spain. Plasmatic levels of soluble tumour necrosis factor receptor II (sTNFR2), interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1 and vascular endothelial growth factor (VEGF) was quantified using cytofluorometry-based ELIAS technique in accordance with manufacturer's instructions using FlowCytomix kit (eBioscience, UAS) at Instituto Maimonides de Investigacion Biomedica de Cordoba – Reina Sofia Hospital, Spain.

Results: According to DAS28 (CRP) all the patient have active arthritis (5.87 $\pm$ 0.6) with median disease duration of 9 (4–14) years. Most of the patients were diagnosed with depression (n=33), 84.8% were female. Anxiety was present at 21 subjects (80.9% female). In 3 cases these two mental disorders coexist.

In a subgroup with depression the polymorphism rs1061631 (GG) was significantly associated with increased level of VEGF (p=0.007). A significant correlation was also found between the polymorphism rs3397 (CC/TT) and MCP-1 level (p=0.01).

In a subgroup with anxiety the significant association was found between the polymorphism rs1061631 (GG) and the level of MCP-1 (p=0.04).

Conclusions: Pro-inflammatory dysregulation might be particularly relevant in some patients with RA and psychiatric illness. Amongst genetic factors that influence the susceptibility to the development of RA and psychiatric disorders some single nucleotide polymorphisms (SNPs) in TNF- α gene have been considered with increasing interest. Further investigation in a larger cohort is needed.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7584

AB0354

FACTORS OF THE POSITIVE OR NEGATIVE ANSWER ON THERAPY WITH DENOSUMAB IN WOMEN WITH RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

I. Dydykina, P. Kovalenko, A. Smirnov, E. Nasonov. *Nasonova Reumatologic Research Institute, Moscow, Russian Federation*

Objectives: To define a contribution of factors: anamnesis, clinical/laboratory markers, glucocorticoids (GC) intake, etc. on the response to therapy with denosumab in women with rheumatoid arthritis (RA) and osteoporosis (OP).

Methods: 66 postmenopausal women (mean age 59.6 $\pm$ 7.4) with RA (mean duration 17.7 $\pm$ 10.4 years) and OP received s/c denosumab 60 mg every 6 months pro 1 year. RF-positive were 72%, ACCP – 74% of patients. 34 (49%) continued GC. At baseline and after 12 months it was carried out the dual energy x-ray absorptiometry at 3 sites: lumbar spine (L1-L4), hip neck (HN) and distal forearm (DF) and x-ray of hands and feet (Sharp/van der Heijde (SVH) score). After therapy it was noted the increase of BMD in L1-L4 and HN, a tendency to increase (p=0.0529) in DF. Positive dynamics (increase or stabilisation of BMD) was noted in 89% patients at L1-L4, 67% – at HN and 60% – at DF. The erosion score was increased in 12% (n=8) patients, the joint space narrowing score (JSN) – in 9% (n=6) (p=0.0117 and p=0.027, respectively). The Statistica 6.0 was used.

Results: Results of analysis of influence of statistically significant factors on the response to therapy in BMD showed that the negative response in L1–L4 is associated with GC intake (>3 months in anamnesis) (p=0.034) and the beginning of GC intake after menopause onset (p=0.023). In HN positive response is associated with higher concentration of the RF (initially and in dynamics) (p<0.05) and the beginning of menopause later than RA onset (p=0.024), the negative response – with GC intake (>3 months in anamnesis) (p=0.024). In DF positive response on therapy is associated with RF-positivity (p=0.02), the negative response back correlates with increase in erosion score and total SVH score: r=0.360 (p<0.05).

In table 1 it is shown the most significant factors, which influence on SVH score dynamics (increase) after 12 months of denosumab therapy.

Abstract AB0354 – Table 1. The factors which influence on SVH score increase (n=66), p<0.05.

SVH score	The score increase is associated with
Erosion score	- lower BMD in L1-L4 (at baseline and after treatment) - higher cumulative GC dose - back correlates with BMD increase in DF - back correlates with bone alkaline phosphatase (BAP) base level - correlates with increase in JSN
Joint space narrowing score (JSN)	- presence at patients in anamnesis a surgical menopause - lower value of BMD dynamics (%) in DF - correlates with increase in erosion score and total SVH score.